Clinical pharmacology of anti-il-17 receptor antibody khk4827 (brodalumab) in Japanese healthy volunteers and subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

被引：0
|
作者：
Nemoto, O. [1 ]
Nagashima, H. [2 ]
Sayama, K. [3 ]
Kobayashi, H. [4 ]
机构：
[1] Sapporo Skin Clin, Sapporo, Hokkaido, Japan
[2] Yanagibashi Hosp, Yanagibashi Clin Trial Ctr, Tokyo, Japan
[3] Ehime Univ, Grad Sch Med, Dept Dermatol, Matsuyama, Ehime 790, Japan
[4] Med Corp Shinanokai, Shinanozaka Clin, Tokyo, Japan
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P049
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetics and safety of PC-SOD, a lecithinized recombinant superoxide dismutase, in healthy Chinese subjects: A phase 1, randomized, placebo-controlled, dose-escalation study (vol 57, pg 596, 2019)
    Chen, Rui
    Zhao, Qian
    Wu, Ni
    Zhong, Wen
    Jin, Xin
    Liu, Chunyan
    Zhu, Zhenyu
    Hu, Pei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (02) : 128 - 128
  • [42] Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
    Christopher John Wynne
    Alexandra Cole
    Charlotte Lemech
    Guoqin Wang
    Yu Zhang
    Benchao Chen
    Max Wang
    Baiyong Li
    Michelle Xia
    Rodney Sinclair
    Dermatology and Therapy, 2023, 13 : 2357 - 2373
  • [43] Safety, Tolerability, and Pharmacokinetics of Nebulized GB05-Human IFNα1b Inhalation Solution: A Randomized, Placebo-Controlled, Dose-Escalation Phase I Study in Healthy Chinese Adult Volunteers
    Peng, Hengxin
    Zhang, Wenjun
    Lin, Yanqing
    Li, Huiming
    Qin, Suofu
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (09) : 2053 - 2070
  • [44] RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study
    Catherine S. Tripp
    Carolyn Cuff
    Andrew L. Campbell
    Barbara A. Hendrickson
    Jeff Voss
    Terry Melim
    Chengbin Wu
    Andrew D. Cherniack
    Kenneth Kim
    Advances in Therapy, 2017, 34 : 1364 - 1381
  • [45] PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE ANTI-NERVE GROWTH FACTOR (NGF) ANTIBODY TANEZUMAB IN SUBJECTS WITH MODERATE TO SEVERE PAIN DUE TO SCHWANNOMATOSIS
    Plotkin, Scott R.
    Da, Jennifer
    Silverman, Danielle
    Merker, Vanessa
    Ly, Ina
    Muzikansky, Alona
    Parsons, Michael
    Wolters, Pamela
    Xu, Lei
    Brown, Mark
    Styren, Scot
    Haghpassand, Mehrdad
    Jordan, Justin T.
    NEURO-ONCOLOGY, 2023, 25
  • [46] RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study
    Tripp, Catherine S.
    Cuff, Carolyn
    Campbell, Andrew L.
    Hendrickson, Barbara A.
    Voss, Jeff
    Melim, Terry
    Wu, Chengbin
    Cherniack, Andrew D.
    Kim, Kenneth
    ADVANCES IN THERAPY, 2017, 34 (06) : 1364 - 1381
  • [47] Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers
    Wu, Min
    Zhang, Hong
    Li, Qianqian
    Chen, Hong
    Fang, Min
    Yang, Lizhi
    Ding, Yanhua
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [48] EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Wei, James Cheng-Chung
    Kim, Tae-Hwan
    Kishimoto, Mitsumasa
    Morishige, Takuya
    Ogusu, Naoki
    Kobayashi, Shigeto
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 195 - 195
  • [49] Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects
    Kalluri, H.
    Zadikoff, C.
    Rueter, L.
    Graff, O.
    Xiong, H.
    MOVEMENT DISORDERS, 2021, 36 : S179 - S179
  • [50] A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers
    Hu, Yue
    Zhang, Hong
    Li, Xiaojiao
    Mai, Jiajia
    Yang, Lizhi
    Yan, Jie
    Li, Ying
    Sun, Jingchao
    Xu, Wenjie
    He, Shiying
    Li, Jinfeng
    Wu, Min
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (09) : 977 - 985
12345